Notes
August 2026: Top 5 Undervalued U.S. Stocks With Improving Fundamentals
2026-08-30
1. Overview
- As of: 2026-08-30
- Stocks reviewed: 10
- Framework: Fundamental improvement 30%, valuation 25%, balance sheet 15%, catalysts 15%, price dislocation 10%, risk 5%.
- Market backdrop: The S&P 500 remains strong in 2026, but several companies have lagged because of company-specific events, sector concerns or high expectations despite improving operating results.
Exact three-month total returns were not consistently verifiable on a common reliable basis for every candidate. Where unavailable, they are explicitly marked unavailable rather than estimated.
2. Candidate Table
| Rank | Ticker | Company | Sector | 3M return / relative | Revenue growth | OPM change | FCF | Balance sheet | Guidance | Valuation | Risk | Catalyst | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PYPL | PayPal Holdings | Fintech | Unavailable; ~-12% on 8/28 event | Q2'26 revenue $8.68B, continued YoY growth | Unavailable | TTM levered FCF ~$4.42B | Cash ~$11.26B | FY26 non-GAAP EPS raised | P/E 11.6x; EV/EBITDA ~5.8-7.5x | Checkout competition | Venmo, margins, buybacks | 84.0 |
| 2 | NVST | Envista Holdings | Dental equipment | Unavailable | Core sales improving | Improving profitability | Q2 FCF $105M vs $76M | Manageable | FY26 sales/EBITDA/EPS raised | Potential peer discount | Dental demand | Guidance delivery, buybacks | 82.5 |
| 3 | CVS | CVS Health | Healthcare | Unavailable; below July high | Q2 +7.3% YoY | GAAP OPM ~+2.0pp YoY | 1H CFO $10.6B | Cash ~$14B | EPS and CFO raised | Forward P/E 12.6x | Medical cost trend | Aetna normalization | 81.0 |
| 4 | UPS | UPS | Logistics | Unavailable | Q2 revenue $22.8B, YoY higher | Adj. margin 9.2%, improved | Unavailable | Investment grade profile | Revenue/profit/EPS raised | Below historical peak multiples | Macro/volume | Network redesign | 79.5 |
| 5 | ZM | Zoom Communications | Software | Unavailable; ~-6% post earnings | Q2 FY27 $1.277B | Unavailable | $472M vs $508M | Cash/securities $7.2B | Next-qtr guide slightly light | Reasonable ex-cash | Consumer slowdown | Enterprise + AI | 77.5 |
| 6 | VNT | Vontier | Industrials | Unavailable | -2.2%; core -0.2% | Unavailable | Adj. FCF $97.6M | Manageable | EPS raised | Low-growth discount | Revenue stagnation | Cost efficiency | 73.0 |
| 7 | CHRD | Chord Energy | Energy | Unavailable | Commodity-driven | Unavailable | Adj. FCF beat expectations | Shareholder returns supported | Operational outlook solid | Low sector multiples | Oil price | Productivity, buybacks | 72.0 |
| 8 | ADSK | Autodesk | Software | +8.6% | +16% YoY | +4.0pp GAAP | $561M, +24% | Sound | Revenue/billings growth raised | Forward P/E 21.4x | Absolute multiple | AI, MaintainX | 71.0 |
| 9 | SPXC | SPX Technologies | Industrials | Unavailable | +51.5%; organic +12.7% | +0.4pp adjusted | $162M, +18% | Acquisition leverage watch | Positive execution | Growth premium | Integration | SPX FLOW synergies | 69.5 |
| 10 | MRVL | Marvell Technology | Semis | Unavailable; ~-10% post-results day | +37% YoY | Improving | Q2 CFO $605.5M | Cash ~$3.93B | Strong, expectations high | Forward P/E ~59.5x | AI valuation | Data center | 60.0 |
3. Final Top 5
PYPL — PayPal Holdings — 8.6/10
PayPal combines raised FY26 non-GAAP guidance, substantial free cash flow, ~$11B cash and a low earnings multiple. The 8/28 acquisition-related selloff created a fresh price dislocation. The market may be underweighting Venmo monetization and cost discipline. Catalysts are branded checkout stabilization, Venmo growth and buybacks. Key risks are Apple Pay competition and continued checkout share loss. Kill condition: renewed structural branded-checkout deterioration plus repeated FCF or transaction-margin-dollar guidance cuts. Watch branded checkout growth, transaction margin dollars and FCF.
NVST — Envista Holdings — 8.4/10
Q2 FCF rose to $105M from $76M and management raised 2026 core sales, EBITDA growth and EPS guidance. The market may be underestimating the pace of margin and cash-conversion normalization. Catalysts include guidance delivery and repurchases. Risks include dental demand and execution. Kill condition: core sales returning negative with an EBITDA-growth guide cut. Watch core sales, adjusted EBITDA margin and FCF conversion.
CVS — CVS Health — 8.2/10
Q2 revenue grew 7.3% and operating income improved sharply while management raised adjusted EPS and cash-flow guidance. The market is still focused on medical-cost risk, but the forward multiple remains modest if Aetna normalization continues. Catalysts are improved benefit margins and deleveraging. Kill condition: renewed medical-cost deterioration forcing EPS/CFO cuts. Watch MBR, adjusted operating income and CFO.
UPS — United Parcel Service — 8.0/10
UPS reported $22.8B of Q2 revenue, a 9.2% adjusted operating margin and raised full-year revenue, operating-profit and EPS targets. Restructuring charges obscure improving underlying economics. Catalysts are network savings and volume stabilization. Risks are macro weakness, Amazon volume changes and labor expense. Kill condition: renewed adjusted-margin deterioration plus a full-year profit guide cut. Watch domestic volume, revenue per piece and adjusted operating margin.
ZM — Zoom Communications — 7.8/10
Zoom's growth is modest, but enterprise revenue remains stronger than consumer revenue, the company holds $7.2B of cash and securities, and quarterly FCF remains very high. The market may be undervaluing enterprise, Contact Center and AI optionality. Risks are Microsoft Teams and persistent low growth. Kill condition: stalled enterprise growth combined with structurally lower FCF margins. Watch enterprise revenue growth, net dollar expansion and FCF margin.
4. Conclusion
- Highest Conviction: PYPL
- Best Risk/Reward: NVST
- Most Conservative: CVS
- Highest Rebound Potential: PYPL
- Needs More Confirmation: ZM
This research is for idea generation only and is not investment advice. Results can differ materially due to data lags, estimate changes, company events, macro conditions and unforeseen market risks.
Not investment advice. Scores and lists are relative snapshots.